Background {#Sec1}
==========

Breast cancer is the most common cancer among women in many regions of India \[[@CR1]-[@CR3]\]. It is highly heterogeneous, with a wide range of biological, pathological, and clinical characteristics \[[@CR4]\]. Among these, hormone receptors (estrogen receptor (ER), progesterone receptor (PR)) greatly influence clinical outcome, and their role as a prognostic and therapeutic tool is widely accepted \[[@CR5],[@CR6]\]. Though the incidence of breast cancer in Kerala has been steadily mounting, data on epidemiology and survival of breast cancer in the state is scarce.

The objectives of this study were to analyze the survival pattern of female breast carcinoma in this region of the country and to compare the differences in survival with different hormone-receptor expressions.

Methods {#Sec2}
=======

A retrospective cohort study was conducted on 189 female patients who were diagnosed with invasive ductal carcinoma and had undergone surgery between 1 August 2008 and 31 July 2009 in the Department of General Surgery, Government Medical College, Thrissur. The required information was collected from the treatment records of the patients maintained at the Medical Records Library. All data including age, menopausal status, and pathological characteristics \[grade (modified Bloom-Richardson grade), stage of the disease (AJCC), tumor size, and axillary nodal status\] were recorded. Patients whose hormone-receptor status was not analyzed were excluded from the study. Patients who had either ER or PR positive tumors were treated with hormonal therapy. Overall survival was calculated in months, either from the date of diagnosis or from the date of surgery up to 31 December, 2013. Five-year survival at the end of the study period was obtained from follow-up records for those who were on regular follow-up and was confirmed by contacting the patients or their relatives over telephone. Those who had been lost to follow-up were also traced over telephone.

All post-mastectomy specimens were evaluated for hormone-receptor expression (ER and PR) by immunohistochemistry. In accordance with the American Society of Clinical Oncology (ASCO) guidelines \[[@CR7]\], which were being followed when the assays were done, specimens in which more than 10% of the tumor-nuclei stained positive were reported hormone-receptor positive. ER status was determined using the BioGenex monoclonal mouse IgG (Clone 1D5) (BioGenex, USA), and PR status was determined using BioGenex monoclonal mouse IgG (Clone 1A6) (BioGenex, USA). Antigen retrieval was done using the BioGenex EZ-Retriever system (BioGenex, USA). Based on hormone-receptor expression, patients were grouped into four categories, that is, ER + PR+ (ER positive PR positive), ER + PR−(ER positive PR negative), ER − PR+ (ER negative PR positive), and ER − PR−(ER negative PR negative).

Pathologic variables were compared using chi-square test. Logistic regression analysis was carried out to assess the independent association between different variables and survival. The Kaplan-Meier method was used to estimate the overall survival.

Results {#Sec3}
=======

One hundred eighty-nine female patients with invasive ductal breast cancer were included in the study. The age of the patients ranged from 27 to 80 with a median of 49.07 ± 10 years. ER expression was seen in 107 patents (56.6%) and PR expression in 113 patients (59.8%).

General characteristics {#Sec4}
-----------------------

The general characteristics of the study group are shown in Table [1](#Tab1){ref-type="table"}. Out of the 189 patients, 111 (58.7%) were pre-menopausal. One hundred twenty-seven patients (67.2%) were between 41 and 60 years of age. Distribution of patients according to their age and hormone-receptor expression is shown in Table [2](#Tab2){ref-type="table"}. A majority (*n* = 127, 67.2%) had stage 2 breast cancer at presentation. One hundred four patients (55%) had grade 2 tumor, and 120 (63.2%) had tumor size between 2 and 5 cm.Table 1**General characteristics of the study populationVariable*N*** **(number)%**MenopausalPre-menopausal11158.73Post-menopausal7841.27GradeI136.8II10455III7238.1StageI115.8II12767.2III5127Tumor sizeT1147.4T212063.2T33417.9T42111.1ER statusER+10756.61ER−8243.39PR statusPR+11360PR−7640Hormone-receptor statusER + PR+10354.5ER + PR−42.1ER − PR+105.3ER − PR−7238.1Table 2**Distribution of patients according to their age and HR expression and their outcomeAge groupTotalER + PR+ER + PR−ER − PR+ER − PR−Survival*N**N*** **(%)*N*** **(%)*N*** **(%)*N*** **(%)*N*** **(%)**21 to 3051 (20)004 (80)1 (20)31 to 403623 (63.8)1 (2.78)3 (8.33)9 (25)27 (72.97)41 to 507946 (58.23)02 (2.53)31 (39.24)59 (75.64)51 to 604820 (41.67)3 (6.25)5 (10.42)20 (41.66)35 (72.91)61 to 701610 (62.5)006 (37.5)11 (68.75)71 to 8053 (60)002 (40)2 (40)Total18910341072

Hormone-receptor expression and outcome {#Sec5}
---------------------------------------

In this breast cancer cohort, 103 patients (54.5%) were ER + PR+, 72 patients (38.1%) were ER − PR−, 10 patients (5.3%) were ER − PR+, and 4 patients (2.1%) ER + PR−. Mean follow-up time was 52 months. 71.4% of the patients (*n* = 135) were found to have survived to five years from the time of diagnosis. Mortality was found to be highest for the ER − PR − group (*n* = 38, 47.2%). Data regarding the four types of hormone-receptor expression and the outcomes of patents that belonged to each group is shown in Figure [1](#Fig1){ref-type="fig"}. Among the different age groups, patients aged 50 years or younger were found to have a higher mortality (Table [2](#Tab2){ref-type="table"}). The Kaplan-Meier survival curve was plotted for the different types of hormone-receptor expression and for overall survival (Figures [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}).Figure 1Pattern of hormone-receptor expression and survival.Figure 2Kaplan-Meier Curve for overall survival.Figure 3Kaplan-Meier Curve for survival for different hormone-receptor expression.

Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"} show the association between different variables and survival in breast cancer. Stage of the disease (adjusted risk ratio (RR) 1.274), nodal status (adjusted RR 1.055), and hormone-receptor status (adjusted RR 2.859) showed statistically significant association with overall survival.Table 3**Association of different variables to survival of breast cancer (univariate analysis)Pathological variables and other factors*P*** **value**Age0.083Menopausal status0.53Tumor size0.164Tumor grade0.084Stage\<0.0001Nodal status0.0001Hormone-receptor status\<0.0001Estrogen receptor0.000Progesterone receptor0.573*P* value \<0.05 significant.Table 4**Association of pathological variables and survival in invasive female ductal carcinoma (multilogistic regression analysis)Adjusted RR95% CI for adjusted RRLowerUpper**Tumor grade1.4510.732.884Axillary nodal status1.3931.0552.571Stage of the disease1.9581.2743.007HR status2.8590.96210.733RR - risk ratio. Cox-Snell *R* ^*2*^ 0.271.

Discussion {#Sec6}
==========

Breast cancer is the most common cancer among urban women and second most common among rural women in India \[[@CR1]\]. Breast cancer is a heterogeneous disease that can be classified into several subtypes on the basis of various clinical and pathological features \[[@CR8]\]. Hormone-receptor (ER and PR) status is now routinely determined for all patients to assess the possibility of providing them specific adjuvant hormone therapy \[[@CR6]\].

The median age of the study group was 49.07 ± 10.35 years, which is very low compared to the USA, where the median age at diagnosis of breast cancer is 61 years \[[@CR9]-[@CR11]\]. This considerable difference can likely be due to the genetic, racial, and socioeconomic differences between the two populations.

Data from the study showed that 56.6% patients were ER+ and 54.5% patients were ER + PR+. This is low when compared to data from the USA, where the overall ER positivity is reported to be 77% \[[@CR10]\]. The findings are consistent with earlier studies from India \[[@CR12]-[@CR15]\]. We also have a higher proportion of ER − PR − tumors compared to the West. It has been noted that ER and PR expression in the study subjects increase with age. This is in concordance with earlier studies \[[@CR16],[@CR17]\]. A greater number of ER − PR − tumors were seen in patients younger than 50 years of age.

Population-based studies on breast cancer in Bangalore \[[@CR18]\] and Chennai \[[@CR19]\] showed five-year survival rates of 42.3% and 48%, respectively. The five-year survival rate of the current study cohort was much higher, at 71.43%. The differences in the survival rate can be explained by differences in the study settings. The USA has an average five-year survival rate of 89.2% for patients diagnosed with breast cancer \[[@CR10]\]. The overall survival rate is still low compared to the West. Five-year survival rates of more than 80% have been reported in many studies from the West and also from a developed Asian country \[[@CR20],[@CR21]\]. Ethnicity and race have been documented as important factors that influence the survival rate \[[@CR22]\]. Along with these factors, well-established screening programs and early detection of the disease also help improve the survival rate.

ER + PR+ breast cancer has been independently associated with decreased breast cancer mortality in many studies \[[@CR4],[@CR19],[@CR23],[@CR24]\]. A similar survival pattern was also noted in the current cohort, with highest mortality in the ER − PR − group.

Stage of the disease, axillary nodal status, and hormone-receptor status showed statistically significant association with overall survival in breast cancer. Among these, the axillary nodal status and stage of the disease are established prognostic factors for carcinoma breast \[[@CR5],[@CR16]\]. Along with their proven role in determining therapeutic course, hormone receptors (ER and PR) can also be used as a predictive tool for breast cancer survival.

ER − PR+ is a rare subtype of breast cancer based on hormone-receptor expression that accounts for 1% to 4% of all cases reported in literature \[[@CR25]\]. The study cohort has a similar fraction of patients (5.3%) with ER − PR+ expression, and 90% survival has been noted in this particular group. The predictive value of PR in the absence of ER expression is controversial \[[@CR26],[@CR27]\]. Some reports suggest that positive PR in the absence of ER has a higher response to hormone therapy, but this finding is not universal \[[@CR28]-[@CR30]\]. Unfortunately, because of the relatively small number of patients in the study group who belonged to this subset, it is difficult to comment on the role of this particular type of receptor expression on disease outcome.

Conclusions {#Sec7}
===========

The overall five-year survival rate of breast cancer patients in Kerala is low compared to developed nations. The lack of an effective cancer screening program is an important reason for this. The higher proportion of hormone-receptor (HR)-negative tumors in our population may be due to delayed diagnosis along with other genetic, ethnic, and cultural variations. Since data on epidemiology and risk factors of the breast cancer in the state is inadequate, it is very crucial to further explore these aspects of the disease to develop a prevention and control strategy to improve the survival rate.
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